Investigating and optimising physical function with weight loss: a multi-arm open-label adaptive platform trial
Latest Information Update: 03 Oct 2024
Price :
$35 *
At a glance
- Drugs Tirzepatide (Primary)
- Indications Dyslipidaemias; Gestational diabetes; Heart failure; Hypertension; Obesity
- Focus Therapeutic Use
- Acronyms The OPAL Trial
- 20 Sep 2024 New trial record
- 18 Sep 2024 Status changed from not yet recruiting to recruiting.